The future of precision medicine part 5: keeping pace with regulation
The first four instalments in this series of articles on precision medicine focused on its challenges and opportunities in general, the importance of large quantities of high quality, diverse data, and some of the particular issues that will be encountered in the translation of research and theory to clinical practice.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
22 October 2025 Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.
2 September 2025 Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
12 June 2025 Judges uphold PTAB’s finding that two Agilent patents are invalid | All claims of patents, which cover guide RNAs, found to be anticipated by prior art.